NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Alfa Cytology's ETES™ Platform for Tumor Immunotherapy
TL;DR
Alfa Cytology's ETES platform offers pharmaceutical partners a competitive edge in developing safer, more effective cancer immunotherapies with reduced systemic toxicity.
The ETES platform uses three functional domains that bind tumor antigens, engage T-cell receptors, and modulate activation only when cancer is present.
This technology advances cancer treatment by precisely targeting tumors while sparing healthy tissue, potentially improving patient outcomes and quality of life.
Alfa Cytology's innovative system harnesses the body's own T-cells to fight cancer through a sophisticated three-domain molecular engineering approach.
Found this article helpful?
Share it with your network and spread the knowledge!
The Endogenous T-cell Engagement System (ETES™) is a platform technology that consists of three functional domains working together to selectively activate endogenous T cells in response to tumor antigens, offering a powerful new tool for preclinical cancer immunotherapy research.
The platform works through a multi-step process: the antigen-binding domain binds to tumor-specific antigens, the TCR binding domain engages the T-cell receptor to activate T-cells without genetic modification, and the co-receptor domain anchors the molecule in the T-cell membrane to modulate activation based on tumor antigen presence, ultimately leading to targeted cancer cell destruction.
The three critical domains are: the Antigen Binding Domain that interacts with tumor-specific antigens, the TCR Binding Domain that initiates regulated T-cell activation, and the Co-Receptor Domain that anchors the molecule in the T-cell membrane and regulates T-cell activity based on cancer antigen presence.
ETES™ overcomes limitations of current systemically active T-cell engagers by utilizing protease-specific activity in the tumor microenvironment to activate therapeutic molecules precisely at the tumor site, enhancing efficacy while minimizing systemic toxicity that plagues first-generation T-cell engagers.
Alfa Cytology offers the platform for preclinical applications including target validation and candidate screening, in vitro and in vivo efficacy studies (including PDX models), pharmacokinetic/pharmacodynamic profiling, and safety and toxicology assessments.
The platform is being offered to partners in the pharmaceutical and biotechnology sectors for preclinical research applications, providing a new tool for developing next-generation tumor immunotherapies.
The platform ensures precise targeting through its antigen-binding domain that binds only to tumor-specific antigens, and the co-receptor domain that activates T-cells only when cancer antigens are present, thereby sparing healthy tissue from immune attack.
By harnessing endogenous T-cells without genetic modification, the platform activates T-cells via their natural pathways, providing a more regulated and potentially safer approach to tumor immunotherapy compared to genetically modified cell therapies.
For more information about the ETES™ platform and its capabilities, visit www.alfacytology.com/etes.
Curated from 24-7 Press Release
